Shalini Shenoy, M.D.  shenoy@wustl.edu

Profile picture
Professor of Pediatrics, Washington University in St. Louis
Hematology and Oncology

phone: (314) 454-6018

Clinical Interests

Dr. Shenoy's research interests are focused on stem cell transplants for non-malignant disorders, reduced intensity transplants, and the immunologic mechanisms of graft rejection, graft versus host disease (GVHD), and immune reconstitution following stem cell transplantation (SCT). These efforts are directed at making SCT safer and better tolerated by reducing associated toxicities, especially as it relates to non-malignant disorders such as hemoglobinopathy. She is the Prinicipal Investigator of national trials of unrelated donor transplantation for severe sickle cell disease termed the SCURT Trial (Bone Marrow Transplant Clinical Trials Network 0601, NHLBI) and thalassemia termed the URTH Trial (Thalassemia Clinical Research Network, NHLBI). Other clinical trials for additional non-malignant disorders such as bone marrow failure syndromes using alternative and minimally mismatched donors are also underway.

Education

  • MBBS, Kasturba Medical College1981
  • MD, Kasturba Medical College1985
  • MD, Louisiana State University Medical Center1991
  • MD, Washington University in St. Louis1996

Training

  • Residency in Pediatrics, Kasturba Medical College1982 - 1985
  • Residency in Pediatrics, Louisiana State University Medical Center1989 - 1991
  • Fellowship in Pediatric Hematology Oncology, Washington University in St. Louis1992 - 1996

Licensure and Board Certification

  • MO, MD
  • Pediatric Hematology Oncology

Honors and Awards

  • American Society of Histocompatibility and Immunogenetics Scholar Award2001 - 2001
  • Fred Saunders Lecture Award, CBMTG2012 - 2012
  • Teresa J Vietti MD Scholar in Pediatrics, Washington University School of Medicine in St. Louis2014 - Pres

Recent Publications view all (100)


Publication Co-Authors

  1. Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia. A Report from the Pediatric Transplant and Cellular Therapy Consortium (PTCTC). Transplant Cell Ther. 2022. PMID:35288346 
  2. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Transplant Cell Ther. 2022;28(3):174.e1-174.e5. PMID:34958973 
  3. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27(8):642-649. PMID:34304802 
  4. Correction: Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. J Clin Immunol. 2020. PMID:32860171 
  5. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Adv. 2020;4(16):3894-3899. PMCID:PMC7448594  PMID:32813873 
  6. Chimerism in the Realm of Hematopoietic Stem Cell Transplantation for Non-malignant Disorders-A Perspective. Front Immunol. 2020;11:1791. PMCID:PMC7438804  PMID:32903736 
  7. Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report. Blood. 2020;135(23):2094-2105. PMCID:PMC7273831  PMID:32268350 
  8. A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study Biology of Blood and Marrow Transplantation. 2020;26(4):712-717. doi:10.1016/j.bbmt.2019.12.723  
  9. Excellent Outcomes Following Hematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome: A PIDTC Report Blood American Society of Hematology. 2020. doi:https://doi.org/10.1182/blood.2019002939   
  10. A Phase 2 Trial of KIR-Mismatched Unrelated Donor Transplantation Using in Vivo T Cell Depletion with Antithymocyte Globulin in Acute Myelogenous Leukemia: Children's Oncology Group AAML05P1 Study. Biol Blood Marrow Transplant. 2020;26(4):712-717. PMCID:PMC7198330  PMID:31870931 
  11. Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. Front Immunol. 2020;11:239. PMCID:PMC7046837  PMID:32153572 
  12. End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings Blood Advances. 2019;10;3(23):4002-4020. doi:10.1182/bloodadvances.2019000883  PMID:31809537 
  13. How I treat sickle cell disease with hematopoietic cell transplantation. Blood. 2019;134(25):2249-2260. doi:10.1182/blood.2019000821  PMID:31697818 
  14. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study Lancet Haematol. 2019;6(11):e585-e596.. doi:10.1016/S2352-3026(19)30154-1  PMID:31495699 
  15. Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Adv. 2019;3(17):2562-2570. PMCID:PMC6737407  PMID:31471325 
  16. Hematopoietic Stem Cell Transplantation: A Neonatal Perspective. Neoreviews. 2019;20(6):e336-e345. PMID:31261097  
  17. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. Biol Blood Marrow Transplant. 2019;25(5):955-964. PMID:30605731 
  18. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biology of Blood and Marrow Transplantation. 2019;25(4):699-711. doi:https://doi.org/10.1016/j.bbmt.2018.11.004  
  19. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biol Blood Marrow Transplant. 2019;25(4):699-711. PMCID:PMC6453753  PMID:30423480 
  20. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica. 2019;104(4):844-854. PMCID:PMC6442962  PMID:30381298 
  21. Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. Biol Blood Marrow Transplant.. 2019. PMID:30639825 
  22. The genetic landscape of severe combined immunodeficiency in the United States and Canada in the current era (2010-2018). J Allergy Clin Immunol. 2019;143(1):405-407. PMCID:PMC6322970  PMID:30193840 
  23. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at 1-year compared to unrelated donors. haematol. 2018. doi:10.3324/haematol.2018.200121  
  24. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients. Biol Blood Marrow Transplant. 2018. PMID:30321596 
  25. Reduced intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies: BMT CTN 1204 Blood. 2018;132(13):1438-1451. doi:https://doi.org/10.1182/blood-2018-01-828277  
  26. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression 2018;24(10):2040-2046. doi:https://doi.org/10.1016/j.bbmt.2018.06.010  
  27. Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.  Biol Blood Marrow Transplant.. 2018;24(7):1313-21.. PMID:29653206 
  28. Hematopoietic stem cell transplantation for sickle cell disease: Progress and challenges. Pediatr Blood Cancer. 2018;e27263. PMID:29797658 
  29. Early Identification of Barriers and Facilitators to Self-Management Behaviors in Pediatric Patients With Sickle Cell Disease to Minimize Hematopoietic Cell Transplantation Complications. J Pediatr Oncol Nurs. 2018;35(3):199-209. doi:10.1177/1043454218762703  PMID:29577801 
  30. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant. 2018;24(3):521-528. PMID:29155316  
  31. Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: A review. Pediatr Transplant. 2018;22(2). doi:10.1111/petr.13142  PMID:29352515 
  32. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant. 2018;24(3):521-528. PMCID:PMC5826854  PMID:29155316 
  33. Unrelated Donor Transplantation in Children with Thalassemia Using Reduced Intensity Conditioning - the URTH Trial. Biol Blood Marrow Transplant. 2018. PMID:29374585 
  34. Poor outcome with hematopoietic stem cell transplantation for bone marrow failure and MDS with severe MIRAGE syndrome phenotype. Blood Adv. 2018;2(2):120-125. PMCID:PMC5787871  PMID:29365320 
  35. Comment on: Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2018;65(1). PMID:28834235 
  36. A Multicenter Retrospective Analysis Stressing the Importance of Long-Term Follow-Up after Hematopoietic Cell Transplantation for B-Thalassemia. Biol Blood Marrow Transplant. 2017;10:1695-1700. doi:10.1016/j.bbmt.2017.06.004  PMID:28627425 
  37. Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence Following Hematopoietic Cell Transplantation for Sickle Cell Disease. Biol Blood Marrow Transplant. 2017. PMID:28882446 
  38. Awareness of cord blood collection and the impact on banking. Pediatr Blood Cancer. 2017;64(7). PMID:28111924 
  39. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial. Biol Blood Marrow Transplant. 2017. PMID:28578010 
  40. Current Results and Future Research Priorities in Late Effects after Hematopoietic Stem Cell Transplantation for Children with Sickle Cell Disease and Thalassemia: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017;23(4):552-561. PMID:28065838 
  41. Surgical technique determines the outcome of the Brescia/Cimino AVF. J Vasc Access. 2017;18(Suppl. 1):1-4. PMID:28297045 
  42. The Second Pediatric Blood and Marrow Transplant Consortium International Consensus Conference on Late Effects after Pediatric Hematopoietic Cell Transplantation: Defining the Unique Late Effects of Children Undergoing Hematopoietic Cell Transplantation for Immune Deficiencies, Inherited Marrow Failure Disorders, and Hemoglobinopathies. Biol Blood Marrow Transplant. 2017;23(1):24-29. PMCID:PMC5267609  PMID:27737772 
  43. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128(21):2561-2567. PMCID:PMC5123194  PMID:27625358 
  44. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016;22(8):1467-72. PMID:27164064 
  45. Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantation". Biol Blood Marrow Transplant. 2016. PMID:27343717 
  46. Unrelated donor stem cell transplantation for transfusion-dependent thalassemia. Ann N Y Acad Sci. 2016;1368(1):122-6. PMCID:PMC4870105  PMID:26999376 
  47. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015. doi:10.1002/ajh.24183  PMID:26348869 
  48. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015;62(7):1270-6. doi:10.1002/pbc.25458  PMID:25755151 
  49. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.03.019  PMID:25840334 
  50. Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. J Pediatr Hematol Oncol. 2015;37(2):e94-e101. doi:10.1097/MPH.0000000000000272  PMCID:PMC4337424  PMID:25333837 
  51. Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders. Curr Opin Pediatr. 2015;27(1):9-17. doi:10.1097/MOP.0000000000000179  PMCID:PMC4403859  PMID:25565572 
  52. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089-94; quiz 3210. doi:10.1182/blood-2013-01-435776  PMID:24511087 
  53. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. Blood. 2014;123(10):1615-20. doi:10.1182/blood-2013-10-535716  PMCID:PMC3945869  PMID:24435046 
  54. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion. Transfusion. 2014;54(2):384-8. doi:10.1111/trf.12258  PMID:23692505 
  55. Exposure of early pediatric trainees to blood and marrow transplantation leads to higher recruitment to the field. Biol Blood Marrow Transplant. 2013;19(9):1399-402. doi:10.1016/j.bbmt.2013.06.021  PMID:23838095 
  56. Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group. Biol Blood Marrow Transplant. 2013;19(9):1279-87. doi:10.1016/j.bbmt.2013.07.006  PMID:23883618 
  57. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant. 2013;19(8):1238-43. doi:10.1016/j.bbmt.2013.05.021  PMCID:PMC3736557  PMID:23751955 
  58. Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants. Stem Cells Transl Med. 2013;2(5):337-40. doi:10.5966/sctm.2012-0180  PMCID:PMC3667562  PMID:23580541 
  59. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-96. doi:10.1056/NEJMoa1203517  PMID:23075175 
  60. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2012;18(8):1265-72. doi:10.1016/j.bbmt.2012.01.019  PMCID:PMC3618440  PMID:22343376 
  61. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-95. doi:10.1182/blood-2011-11-393975  PMCID:PMC3383014  PMID:22566601 
  62. Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus. Pediatr Blood Cancer. 2012;58(6):988-91. doi:10.1002/pbc.23187  PMID:21618414 
  63. Hematopoietic stem cell transplantation for sickle cell disease: current practice and emerging trends. Hematology Am Soc Hematol Educ Program. 2011;2011:273-9. doi:10.1182/asheducation-2011.1.273  PMID:22160045 
  64. Advancement of pediatric blood and marrow transplantation research in North America: priorities of the Pediatric Blood and Marrow Transplant Consortium. Biol Blood Marrow Transplant. 2010;16(9):1212-21. doi:10.1016/j.bbmt.2009.12.536  PMCID:PMC2891395  PMID:20079865 
  65. Severe sickle cell disease--pathophysiology and therapy. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S64-7. doi:10.1016/j.bbmt.2009.10.001  PMCID:PMC2832723  PMID:19819341 
  66. Acquired monosomy 7 myelodysplastic syndrome in a child with clinical features suggestive of dyskeratosis congenita and IMAGe association. Pediatr Blood Cancer. 2010;54(1):154-7. doi:10.1002/pbc.22283  PMID:19760774 
  67. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplant. 2009;43(4):307-14. doi:10.1038/bmt.2008.327  PMCID:PMC2792985  PMID:19011666 
  68. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008;42(3):159-65. doi:10.1038/bmt.2008.151  PMID:18500373 
  69. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50(4):822-5. doi:10.1002/pbc.21264  PMID:17570702 
  70. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008;41(4):349-53. doi:10.1038/sj.bmt.1705926  PMID:18026148 
  71. Stem cell transplantation in genetically linked regulatory T-cell disorders. Chem Immunol Allergy. 2008;94:211-9. doi:10.1159/000155089  PMID:18802350 
  72. Hematopoietic stem cell transplantation for childhood malignancies of myeloid origin. Bone Marrow Transplant. 2008;41(2):141-8. doi:10.1038/sj.bmt.1705961  PMID:18176616 
  73. Has stem cell transplantation come of age in the treatment of sickle cell disease? Bone Marrow Transplant. 2007;40(9):813-21. doi:10.1038/sj.bmt.1705779  PMID:17704797 
  74. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(10):1201-6. doi:10.1016/j.bbmt.2007.06.012  PMID:17889357 
  75. Successful bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. Blood. 2007;109(1):383-5. doi:10.1182/blood-2006-05-025072  PMID:16990602 
  76. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage. Transfusion. 2006;46(1):14-23. doi:10.1111/j.1537-2995.2005.00665.x  PMID:16398726 
  77. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7(2):143-6. doi:10.109701.GIM.0000154299.22120.6A  PMID:15714083 
  78. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35(4):345-52. doi:10.1038/sj.bmt.1704795  PMID:15592491 
  79. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19(1):34-8. doi:10.1038/sj.leu.2403566  PMID:15510203 
  80. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant. 2003;9(11):714-21. doi:10.1016/j.bbmt.2003.08.006  PMID:14652855 
  81. Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. Blood. 2003;101(5):2067-9. doi:10.1182/blood-2002-07-2110  PMID:12406871 
  82. Antibodies to 70 kD and 90 kD heat shock proteins are associated with graft-versus-host disease in peripheral blood stem cell transplant recipients. Clin Exp Immunol. 2002;127(3):553-9. PMCID:PMC1906313  PMID:11966775 
  83. Defective apoptosis in lymphocytes and the role of IL-2 in autoimmune hematologic cytopenias. Clin Immunol. 2001;99(2):266-75. doi:10.1006/clim.2001.5017  PMID:11318598 
  84. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood. 2000;95(11):3605-12. PMID:10828051 
  85. Allogeneic peripheral blood stem cell transplantation following CD34+ enrichment by density gradient separation. Bone Marrow Transplant. 2000;25(12):1223-8. doi:10.1038/sj.bmt.1702427  PMID:10871725 
  86. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr. 2000;136(5):682-7. doi:10.1067/mpd.2000.105355  PMID:10802504 
  87. Light microscopic, immunophenotypic, and molecular genetic study of autoimmune lymphoproliferative syndrome caused by fas mutation. Pediatr Dev Pathol. 2000;3(1):101-9. PMID:10594139 
  88. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant. 1999;23(4):335-46. doi:10.1038/sj.bmt.1701581  PMID:10100577 
  89. T gamma/delta hepatosplenic lymphoma in a heart transplant patient after an Epstein-Barr virus positive lymphoproliferative disorder: a case report. Cancer. 1998;82(5):983-92. PMID:9486591 
  90. A single‐center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease Pediatric Blood & Cancer 2019; ePub October 10.. PMID:31599480 
  91. Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease. Blood. 136(5):623-6.. doi:doi: 10.1182/blood.2020005687.  PMID:32518950 
  92. Familial Haploidentical Stem Cell Transplant in Children and Adolescents With High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial JAMA Pediatr. 174(2):195-7.. doi:doi: 10.1001/jamapediatrics.2019.4715  PMID:31816036 
  93. Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease. Blood Adv. 4(16):3894-3899. doi:doi: 10.1182/bloodadvances.2020002236.  PMID: 32813873 
  94. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies Blood. 132(13):1438-51. PMID:29997222 
  95. Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression Biol Blood Marrow Transplant. 24(10):2040-2046. PMID:29933069 
  96. How I treat sickle cell disease with hematopoietic cell transplantation.

    Blood. 2019 Dec 19;134(25):2249-2260. doi: 10.1182/blood.2019000821. Blood. 134(25):2249-60. PMID:31697818 

  97. Analysis of graft-versus-host disease (GVHD) and graft rejection using MHC class I-deficient mice. Clin Exp Immunol 1998. 112(2):188-95. PMID:9649180 
  98. Chimerism in the Realm of Hematopoietic Stem Cell Transplantation for Non-malignant Disorders-A Perspective Front Immunol. 11:1791. doi:10.3389/fimmu.2020.01791  PMID:32903736  
  99. Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: graft-versus-host disease and transplant-related mortality. J Clin Oncol 1999. 17(3):806-12.. PMID:10071270 
  100. Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions. Ther Adv Hematol 2013. 4(5):335-44. PMID:24082994 
Last updated: 03/31/2022
© 2022 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130